Agilent Licenses Roswell Park-developed blood cancer test (Genomeweb)
"Roswell Park Cancer Center said this week that Agilent Technologies has licensed its blood cancer assay, PanHeme...Under the licensing agreement, Agilent is now able to commercialize the assay worldwide, supported by its SureSelect XT HS2 library preparation and target enrichment chemistry, Magnis NGS Prep system, Bravo automation platform, and Alissa secondary analysis software."